Skip to content

XERIS BIOPHARMA HOLDINGS, INC.

XERS

CIK 0001867096

← back to feed
Revenue (TTM)
$289.17M
+43.7% YoY Q1 Apr 2026
Net Income (TTM)
−$8.29M
+101.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.06
+100.0% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
5.5%
Q1 Apr 2026
Net Margin
-2.9%
Q1 Apr 2026
Free Cash Flow (TTM)
−$69.96M
Q1 Apr 2026
Cash
$111.75M
Q1 Apr 2026
Total Debt
$221.22M
Q1 Apr 2026
Shares Outstanding
172.64M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings